CHARGED ALPHATMFrontier AI stock research

TRUMY · OTC Markets OTCPK

Terumo Corporation

Medical Devices · Japan

USD 14.441.6% daily changeQuote 2026-10-05 · USD
Market cap (USD)
US$21.30B
Trailing P/E
23.67x
Forward P/E
—
Quarterly revenue growth
19.9%
Trailing net margin
13.9%
Indicated dividend yield
1.3%

Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-11-12 (provider estimate, not issuer-confirmed).

Company background

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The Terumo Organ Technologies segment provides organ preservation devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Shibuya, Japan.

Company website

Q1 2026

Go beyond the headline.

TRUMY Stock: EPS Misses Estimates — Q1 2026

Published 2026-05-15

Comparable businesses

TRUMY peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.

Market metrics · missing or inapplicable values shown as —
MetricTRUMYTerumo CorporationSnapshot 2026-10-06Financial period: 2026-06-30
Market capMarket value, converted to USDUS$21.30B
Forward P/EProvider forward earnings estimate—
EV / EBITDAEnterprise value / trailing EBITDA—
Revenue growthLatest quarter vs prior-year quarter19.9%
Operating marginLatest reported quarter28.7%
Free cash flow yieldTrailing cash flow / market cap—
Net debt / EBITDANet debt / trailing EBITDA0.40x
Debt / equityTotal debt / positive book equity0.26x
Trailing P/ETrailing twelve-month earnings23.67x
Price / bookPrice / positive book equity per share2.12x
EV / salesEnterprise value / trailing revenue—
Earnings growthLatest quarter vs prior-year quarter68.3%
Gross marginTrailing twelve months53.2%
Net marginTrailing twelve months13.9%
Return on equityProvider trailing return; positive equity only10.9%
Free cash flow marginTrailing free cash flow / revenue8.1%
Dividend yieldIndicated annual dividend / price1.3%
Earnings payoutProvider trailing dividend payout31.2%
Current ratioCurrent assets / current liabilities2.19x
BetaProvider historical market sensitivity0.31

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for TRUMY

All available reporting periods
Q1 20262026-05-15

TRUMY Stock: EPS Misses Estimates — Q1 2026

Presentation · 2026-05-15 · YouTube

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.